Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Recruiting

Phase 1

Phase 2

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Sponsor:

Tyra Biosciences, Inc

Code:

NCT05544552

Conditions

Locally Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Solid Tumor

Urothelial Carcinoma

Solid Tumor, Adult

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TYRA-300

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Tyra Biosciences, Inc on 2024-10-03.